Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure

NCT07562087 is registered in ClinicalTrials.gov with Tarsus Pharmaceuticals, Inc. as lead sponsor.

NCT NCT07562087
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07562087 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TP-05 in Healthy Participants at High Risk of Tick Exposure
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
March 9, 2026
Completion date
December 31, 2027
Enrollment
722 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

lyme disease